Last reviewed · How we verify
NCT06980519
MNPR-101-PCTA-177Lu Expanded Access Program (EAP) for Patients With Solid Tumor Cancer
trial testing MNPR-101-PCTA-177Lu in Cancer. Available.
Quick facts
| Lead sponsor | Monopar Therapeutics |
|---|---|
| Status | AVAILABLE |
| Study type | EXPANDED_ACCESS |
| Sites | 1 location across United States |
Drugs / interventions tested
- MNPR-101-PCTA-177Lu — full drug profile →
Conditions studied
- Cancer — all drugs for Cancer →
- Solid Tumor — all drugs for Solid Tumor →
- Solid Tumor Cancer — all drugs for Solid Tumor Cancer →
- Oncology — all drugs for Oncology →
Sponsor
Monopar Therapeutics — full company profile →
Who can join
18 and older, any sex, with Cancer or Solid Tumor. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The purpose of this Expanded Access Program (EAP) is to allow use of the investigational therapeutic agent, MNPR-101-PCTA-177Lu, for treatment of urokinase plasminogen activator receptor (uPAR)-positive solid tumors identified via positron emission tomography / computed tomography (PET/CT) with investigational imaging agent MNPR-101-DFO\*-89Zr.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
Emerging Diagnostics and Therapies in Neuroendocrine Neoplasms: A Critical Review.
Hernandez-Felix JH, Meneses-Medina MI, Riechelmann R, Strosberg J, et al · · 2025 · cited 1× · PMID 41300999 · DOI 10.3390/cancers17223632
Verify or expand the search:
- PubMed search for NCT06980519
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Cancer
Currently open trials in the same condition.
- NCT07390045 — Exercise and Cognitive Rehabilitation Interventions for Older Cancer Survivors · NA · recruiting
- NCT07528547 — Hypersight and Ethos In Pediatric Radiotherapy · NA · recruiting
- NCT07481890 — Feasibility and Efficacy of the EMDR Toolbox Method in Cancer Patients. · NA · recruiting
- NCT07402057 — Implementation and Evaluation of a Program Aimed at Facilitating Palliative Care Conversations · NA · recruiting
- NCT07305740 — On-Trac: An Online Intervention for Cancer Survivors Managing Anxiety · NA · recruiting
Other Monopar Therapeutics trials
Trials by the same sponsor.
- NCT05043649 — Camsirubicin + Pegfilgrastim to Determine MTD in ASTS · Phase 1 · terminated
- NCT04648020 — Clonidine HCl MBT vs. Placebo to Prevent Chemoradiotherapy-Induced Severe Oral Mucositis in Oropharyngeal Cancer. · Phase 2, PHASE3 · terminated
- NCT06980506 — MNPR-101-DFO*-89Zr Expanded Access Program (EAP) for Patients With Solid Tumor Cancer · available
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06980519 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Monopar Therapeutics
- Last refreshed: 22 May 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06980519.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing